Compare Crispr Therapeutics AG (CRSP) vs GXO Logistics Inc (GXO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs GXO Logistics Inc — how do they compare? Crispr Therapeutics AG trades at $53.51 (market cap $4.88B), while GXO Logistics Inc trades at $46.63 (market cap $5.32B). The key difference: Crispr Therapeutics AG and GXO Logistics Inc are close in size by market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, GXO Logistics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and GXO Logistics Inc for 28 Days on average.
| CRSP | GXO | |
|---|---|---|
Market Cap | $4.88B | $5.32B |
Volume | 2,861,747 | 1,255,816 |
Sector | Health | Industrials |
52-Week High | $74.92 | $65.59 |
52-Week Low | $44.34 | $44.17 |
Typical Hold Time | 77 Days | 28 Days |
Enterprise Value | $3.30B | $10.67B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.41, up 2.02% with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with -$581.60M net income in 2025 and revenue volatility, though analyst consensus remains bullish with a $67.83 price target. Key catalysts include upcoming clinical data presentations for autoimmune disease therapies and CASGEVY commercialization progress.
The stock presents high-risk, high-reward potential with strong Wall Street support (57.9% buy ratings) but faces significant execution risks. Near-term performance hinges on clinical trial outcomes and revenue generation from approved therapies, while persistent cash burn and competitive pressures remain key concerns for investors.
GXO trades at $46.47, up 1.04% with neutral technical indicators and strong analyst support. The company shows improving fundamentals with Q2 2026 revenue of $3.4 billion (up 4% YoY) and three consecutive earnings beats. Recent strategic partnerships with Columbia Sportswear and technology investments in labor management systems position GXO for operational efficiency gains. The stock trades at a P/E of 41.03 and P/S of 0.39, reflecting growth expectations amid modest current profitability.
GXO presents a compelling growth story with 88.9% analyst buy ratings and a $66.67 consensus price target (43% upside). However, margin compression remains a concern as new business wins show lower incremental profitability. The company's expansion in aerospace/defense and European logistics markets provides growth catalysts, but investors should monitor execution on the 6% EBIT margin target and supply chain industry headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About GXO Logistics Inc
GXO is the world's largest pure-play contract logistics provider. It offers cutting-edge supply chain solutions, including automated warehousing and fulfillment, for global blue-chip companies.
Read more on GXO →
